Study of SHR-A1811 for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called SHR-A1811 for ovarian cancer. It may help people whose cancer can be measured on scans and who are still well enough to do daily activities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian cancer that can be seen on scans.
- You are able to do your daily activities with little or no help.
- Your doctor expects you to live at least 12 more weeks.
- You do not have untreated or active brain metastases.
- You do not have uncontrolled heart disease.
- You do not have active hepatitis B or C.
- You do not have a serious active infection like tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new drug, SHR-A1811, for ovarian cancer that came back after responding well to platinum chemo. It is for people with BRCA mutations or HRD positive status who have already tried a PARP inhibitor.
This trial tests a new targeted drug (SHR-A1811) against standard chemotherapy for ovarian cancer that no longer responds to platinum drugs. It's for people whose tumors have a specific protein called HER2, and who have had limited prior treatments after platinum resistance.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug, SHR-A1921, given alone or with chemotherapy (carboplatin) for people with ovarian cancer that has come back or spread. It aims to see if this combination works better than standard treatments.
This Phase 2 trial tests SHR-A1811, a cancer medicine, in people with advanced or returning cervical, ovarian, or endometrial cancer. It may help shrink tumors, depending on whether you meet study safety and eligibility requirements.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.